European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer
Vegzelma™ offers European patients living with certain types of breast, lung, renal, colon, rectum, ovarian and cervical cancers a new, safe, and effective treatment option at an affordable price Approval is based on clinical trial data demonstrating Vegzelma™ is highly similar to Avastin®1 (bevacizumab) Vegzelma™ is Celltrion’s third oncology biosimilar approved by the European Commission … [Read more…]
